

Systematic Modeling of Drug P-Glycoprotein Interactions via Combined Docking/QM Approach

Zahra Hosseinzadeh^a, Ali Ramazani^a, Nima Razzaghi-Asl^{b*}

Authors' Affiliations:

^a Department of Chemistry,
University of Zanjan, Zanjan, Iran;

^b Department of Medicinal
Chemistry, Ardabil University of
Medical Sciences Ardabil, Iran;

Abstract Presenter:

Zahra Hosseinzadeh; PhD;
Department of Chemistry, University
of Zanjan, Zanjan, Iran;
E-mail:
zahra.hosseinzadeh1988@gmail.com
Mailing address: Department of
Chemistry, University of Zanjan,
Zanjan, Iran;

*Correspondence:

Nima Razzaghi-Asl; PhD;
Department of Medicinal Chemistry,
School of Pharmacy, Ardabil
University of Medical Sciences;
E-mail:
n.razzaghi@pharmacy.arums.ac.ir
Mailing address: School of
Pharmacy, Ardabil University of
Medical Sciences, Ardabil, PO Box:
5618953141

Abstract

Introduction: The overexpression of P-gp in cancer tumor cells results in increased efflux of chemotherapeutic compounds. This phenomenon leads to the wide-spectrum resistance of cancer cells to variant drugs or multi drug resistance (MDR). Regarding the important biological role of P-gp with regard to cancer therapy, *in silico* analysis of binding affinity/mode of diverse anticancer drugs toward P-gp may be an active area of research since it provides more insight into the binding interactions and key amino acid residues that were involved.

Methods and Results: Ligand-flexible docking studies were performed using the molecular docking software, AutoDock 4.2. To elucidate the interactions of selected anticancer drugs, all the related structures were docked into the active site of validated P-gp target (4XWK). Quantum mechanical calculations were applied to intermolecular binding energy analysis in terms of drug-residue binding interactions via functional B3LYP in association with split valence basis set using polarization functions (Def2-SVP).

Mitomycin was found to be the weakest binder with -7.29 kcal/mol energy. Bisantrene was the top-ranked binder (-10.59 kcal/mol) with H-bond and lipophilic interaction patterns. To explain more, Asn838 participated in bidentate H-bonding with nitrogen atom of imidazole ring. Another H-bond interaction was detected in the case of Ser725 within the same ring but different nitrogen atom of the drug molecule. Besides hydrogen bonding, it was revealed that 12 hydrophobic residues interacted with Bisantrene. Within the evaluated drugs, unlike Etoposide E and F, no H-bonds could be detected for Etoposide A, B, C & D. Such observation was pertained to the presence of hydroxymethyl moiety on the thiazole ring of Etoposide E and F which provided well-oriented H-bonds with Ala307. Despite observed interactive residues, lower binding affinity of Etoposide F persuaded us to run QM job in terms of drug-residue binding interactions. It was interestingly concluded that a few residues made repulsive forces with the drug, a result that might explain lower affinity of this molecule toward P-gp.

Conclusions: Collective *in silico* exploration of a few anticancer drugs provided some insights into the binding mode toward P-gp as an interfering target in chemotherapeutic strategies. On the basis of obtained results, structure binding relationship pattern for studied anticancer drugs were developed.

Key words: Cancer; MDR; P-gp; Docking; B3LYP

Grants: Supports of this project by Ardabil University of Medical Sciences are acknowledged.